Morgan Stanley Starts Prime Medicine (PRME) at Equalweight
Tweet
Share
E-mailGet Alerts PRME Hot Sheet
Price: $3.17 --0%
Rating Summary:
11 Buy, 5 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 6 | Down: 10 | New: 23
Rating Summary:
11 Buy, 5 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 6 | Down: 10 | New: 23
Join SI Premium – FREE
Morgan Stanley analyst Matthew Harrison initiates coverage on Prime Medicine (NASDAQ: PRME) with a Equalweight rating and a price target of $23.00.
For an analyst ratings summary and ratings history on Prime Medicine click here. For more ratings news on Prime Medicine click here.
Shares of Prime Medicine closed at $21.12 yesterday.
You May Also Be Interested In
- Barclays Starts Centrus Energy Corp. (LEU) at Equalweight
- Prime Drink Group Provides Bi-Weekly MCTO Status Report
- Wolfe Research Starts First Tracks Biotherapeutics (TRAX) at Outperform
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
